Literature DB >> 21432394

Gene-environmental interactions: Lessons from porphyria.

Shigeru Sassa1.   

Abstract

The porphyrias are uncommon, complex, and fascinating metabolic conditions, caused by deficiencies in the activities of the enzymes of the heme biosynthetic pathway. Two cardinal symptoms of the porphyrias are cutaneous photosensitivity and neurologic disturbances. Molecular analysis of gene defects has shown that there are multiple and heterogeneous mutations in each porphyria. Patients with symptomatic porphyria can suffer greatly, and, in rare cases, may die. While congenital porphyrias are inherited, other forms of porphyria occur as acquired diseases. In addition, not all gene carriers of inherited porphyrias develop clinical disease and there is a significant interplay between the gene defect and acquired or environmental factors. The variable response of porphyrias to acquired factors may, likely reflect genetic polymorphisms in drug metabolism. The lessons from acute hepatic porphyria, such as acute intermittent porphyria, are very useful in clarifying the complex nature of the clinical expression of metabolic disorders.

Entities:  

Keywords:  CYP; acute intermittent porphyria; cytochrome P450; gene-environmental interaction; polymorphism; porphyria

Year:  2003        PMID: 21432394      PMCID: PMC2723464          DOI: 10.1007/BF02908884

Source DB:  PubMed          Journal:  Environ Health Prev Med        ISSN: 1342-078X            Impact factor:   3.674


  30 in total

1.  FACTORS AFFECTING THE EXCRETION OF PORPHYRIN PRECURSORS BY PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA. I. THE EFFECT OF DIET.

Authors:  F H WELLAND; E S HELLMAN; E M GADDIS; G COLLINS; G W HUNTER; D P TSCHUDY
Journal:  Metabolism       Date:  1964-03       Impact factor: 8.694

2.  Decreased liver cytochrome P-450 in rats caused by norethindrone or ethynyloestradiol.

Authors:  I N White; U Muller-Eberhard
Journal:  Biochem J       Date:  1977-07-15       Impact factor: 3.857

Review 3.  Cytochrome P450 and its interactions with the heme biosynthetic pathway.

Authors:  F De Matteis; G S Marks
Journal:  Can J Physiol Pharmacol       Date:  1996-01       Impact factor: 2.273

Review 4.  Anaesthesia for the porphyric patient.

Authors:  G G Harrison; P N Meissner; R J Hift
Journal:  Anaesthesia       Date:  1993-05       Impact factor: 6.955

5.  Chemotherapy in porphyria.

Authors:  B Samuels; W R Bezwoda; D P Derman; G Goss
Journal:  S Afr Med J       Date:  1984-06-09

6.  Acute intermittent porphyria: effect of diet and griseofulvin.

Authors:  B F Felsher; A G Redeker
Journal:  Medicine (Baltimore)       Date:  1967-03       Impact factor: 1.889

Review 7.  Drug treatment in acute porphyria.

Authors:  A Gorchein
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

8.  Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.

Authors:  R Kauppinen; P Mustajoki
Journal:  Medicine (Baltimore)       Date:  1992-01       Impact factor: 1.889

9.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  General anesthesia in "inducible" porphyrias.

Authors:  P Mustajoki; J Heinonen
Journal:  Anesthesiology       Date:  1980-07       Impact factor: 7.892

View more
  1 in total

1.  Iron Hack - A symposium/hackathon focused on porphyrias, Friedreich's ataxia, and other rare iron-related diseases.

Authors:  Gloria C Ferreira; Jenna Oberstaller; Renée Fonseca; Thomas E Keller; Swamy Rakesh Adapa; Justin Gibbons; Chengqi Wang; Xiaoming Liu; Chang Li; Minh Pham; Guy W Dayhoff Ii; Ben Busby; Rays H Y Jiang; Linh M Duong; Luis Tañón Reyes; Luciano Enrique Laratelli; Douglas Franz; Segun Fatumo; Atm Golam Bari; Audrey Freischel; Lindsey Fiedler; Omkar Dokur; Krishna Sharma; Deborah Cragun
Journal:  F1000Res       Date:  2019-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.